BMY (STOCKS)
Bristol-Myers Squibb Co.
$58.028300
-0.591700 (-1.01%)
Prev close: $58.620000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Christopher S. Boerner
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $118,533.22M
- Employees
- 34,100
- P/E (TTM)
- 16.94
- P/B (TTM)
- 6.46
- Dividend Yield
- 424.77%
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
9
Buy
19
Hold
2
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$1.26 | $1.13 | +0.1335 | +11.85% |
|
Sep 2025 (Q3)
|
$1.63 | $1.52 | +0.1056 | +6.93% |
|
Jun 2025 (Q2)
|
$1.46 | $1.08 | +0.3789 | +35.05% |
|
Mar 2025 (Q1)
|
$1.80 | $1.51 | +0.2920 | +19.36% |
Financial Statements
| Revenues | $48.19B |
| Benefits Costs and Expenses | $38.87B |
| Cost Of Revenue | $13.94B |
| Costs And Expenses | $38.87B |
| Gross Profit | $34.26B |
| Operating Expenses | $24.93B |
| Selling, General, and Administrative Expenses | $7.27B |
| Research and Development | $9.95B |
| Other Operating Expenses | $7.71B |
| Operating Income/Loss | $9.33B |
| Income/Loss Before Equity Method Investments | $9.28B |
| Income/Loss From Continuing Operations After Tax | $7.06B |
| Income/Loss From Continuing Operations Before Tax | $9.33B |
| Income/Loss From Equity Method Investments | $47.00M |
| Income Tax Expense/Benefit | $2.27B |
| Income Tax Expense/Benefit, Current | $3.24B |
| Income Tax Expense/Benefit, Deferred | -$965.00M |
| Net Income/Loss | $7.06B |
| Net Income/Loss Attributable To Noncontrolling Interest | $1.00M |
| Net Income/Loss Attributable To Parent | $7.05B |
| Net Income/Loss Available To Common Stockholders, Basic | $7.05B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $3.47 |
| Diluted Earnings Per Share | $3.46 |
| Basic Average Shares | 2,034,000,000 |
| Diluted Average Shares | 2,039,000,000 |
| Assets | $90.04B |
| Current Assets | $29.39B |
| Accounts Receivable | $11.41B |
| Inventory | $2.69B |
| Other Current Assets | $15.29B |
| Noncurrent Assets | $60.65B |
| Fixed Assets | $7.54B |
| Intangible Assets | $19.10B |
| Other Non-current Assets | $34.00B |
| Liabilities | $71.53B |
| Current Liabilities | $23.42B |
| Accounts Payable | $3.58B |
| Wages | $1.56B |
| Other Current Liabilities | $18.28B |
| Noncurrent Liabilities | $48.12B |
| Long-term Debt | $44.83B |
| Other Non-current Liabilities | $3.29B |
| Equity | $18.51B |
| Equity Attributable To Noncontrolling Interest | $33.00M |
| Equity Attributable To Parent | $18.47B |
| Liabilities And Equity | $90.04B |
| Net Cash Flow From Operating Activities | $14.16B |
| Net Cash Flow From Operating Activities, Continuing | $14.16B |
| Net Cash Flow From Investing Activities | -$4.13B |
| Net Cash Flow From Investing Activities, Continuing | -$4.13B |
| Net Cash Flow From Financing Activities | -$10.35B |
| Net Cash Flow From Financing Activities, Continuing | -$10.35B |
| Exchange Gains/Losses | $195.00M |
| Net Cash Flow | -$129.00M |
| Net Cash Flow, Continuing | -$324.00M |
| Comprehensive Income/Loss | $6.77B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $2.00M |
| Comprehensive Income/Loss Attributable To Parent | $6.77B |
| Other Comprehensive Income/Loss | -$286.00M |